119th Congress · introduced in the House · May 20, 2025
Clinical Trial Modernization Act
Official title from Congress.gov
Latest action (May 20, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (May 20, 2025)
Clinical Trial Modernization Act
This bill authorizes a grant program and provides certain exemptions to support the participation of individuals in clinical trials.
Specifically, the bill authorizes a grant program to support outreach, education, and recruitment efforts for clinical trials that may benefit certain underrepresented populations or communities in need, such as rural or tribal areas.
The bill also exempts from anti-kickback laws for federal health care programs (1) remuneration that is offered to cover participants' expenses to participate in clinical trials, (2) the provision of free digital health technologies to support participation of underrepresented populations in clinical trials, and (3) payment for participants' cost-sharing obligations in relation to clinical trials.
Finally, the bill exempts up to $2,000 in remuneration that is received for participating in a clinical trial from income tax.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
97 citations; showing the 25 most recently posted.
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN · lobbying firm or registrant: THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 23, 2026 · issue area: Health Issues
$70,000
Spent on own lobbying
…amend title 39, United States Code, to extend the authority of the United States Postal Service to issue a semipostal to raise funds for breast cancer research H.R.3521/S.4440 - Clinical Trial Modernization Act; a bill to modernize clinical trials and remove barriers for participation in clinical trials, and for other purposes…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EPILEPSY FOUNDATION · lobbying firm or registrant: EPILEPSY FOUNDATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$90,000
Spent on own lobbying
…in research -Support legislation and policy preserving charitable giving -S. 3607/H.R. 6280, Access to Genetic Counselor Services Act, support passage -S. 4440/H.R. 3521, Clinical Trial Modernization Act, support passage -Support legislation and regulations that protect Medicaid Home- and Community-Based Services (HCBS) and inc…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Health Issues
$2,560,000
Spent on own lobbying
…Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---FDA Hiring Fl…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL MARROW DONOR PROGRAM · lobbying firm or registrant: NATIONAL MARROW DONOR PROGRAM
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$310,000
Spent on own lobbying
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for and remote acc…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY · lobbying firm or registrant: MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$610,000
Spent on own lobbying
H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$7,040,000
Spent on own lobbying
…ial Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,530,000
Spent on own lobbying
…ial Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY ACTION NETWORK, INC. · lobbying firm or registrant: WILLIAMS AND JENSEN, PLLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
General cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research. Clinical Trial Modernization Act (HR 3521/S.4440).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
JOHNSON & JOHNSON SERVICES INC · lobbying firm or registrant: JOHNSON & JOHNSON SERVICES, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$2,220,000
Spent on own lobbying
…g Patient Access to Cancer and Complex Therapies Act, regarding all provisions - S.1399 / H.R. 6197, the Health Tech Investment Act, regarding all provisions - H.R. 3521, the Clinical Trial Modernization Act, regarding all provisions - H.R. 3006 / S.1776, the Medicare Beneficiary Co-Pay Fairness Act, regarding all provisions -…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF HEMATOLOGY · lobbying firm or registrant: AMERICAN SOCIETY OF HEMATOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$100,000
Spent on own lobbying
…practices for individuals with hematologic disorders OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034) Clinical Trial Modernization Act (H.R. 3521 / S. 4440)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTRAZENECA PHARMACEUTICALS LP · lobbying firm or registrant: ASTRAZENECA PHARMACEUTICALS LP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$810,000
Spent on own lobbying
HR 3521/ S 4440 Clinical Trial Modernization Act HR 946/S 1862 Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act Discuss Vaccine concerns Cell Therapy…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN LUNG ASSOCIATION · lobbying firm or registrant: AMERICAN LUNG ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$70,000
Spent on own lobbying
…Act of 2025; S 77 Early Participation in Regulations Act; S 81 Guidance Clarity Act; HR 77 Midnight Rules Relief Act; H.R. 3701 Family Vaccine Protection Act; H.R. 3521 Clinical Trial Modernization Act; HR 4417 Mobile Cancer Screening Act HR 3701 Family Vaccine Protection Act; HR 5304Departments of Labor, Health and Human Serv…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN LUNG ASSOCIATION · lobbying firm or registrant: AMERICAN LUNG ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$70,000
Spent on own lobbying
…ss to Quality Cardiac Rehabilitation Care Act of 2025; S 77 Early Participation in Regulations Act; S 81 Guidance Clarity Act; HR 77 Midnight Rules Relief Act; H.R. 3521 Clinical Trial Modernization Act; HR 4417 Mobile Cancer Screening Act; HR 5304 Departments of Labor, Health and Human Services, and Education, and Related Agen…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) · lobbying firm or registrant: BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$120,000
Spent on own lobbying
HJRes 197 / SJRes 197, CRA related to the 2027 NBPP; HR 247 / S 46, Health Care Affordability Act; HR 6867 / S 3562, the NIH Clinical Trial Integrity Act; HR 3521 / S 4440, the Clinical Trial Modernization Act; HR 4710 / S 2420, No Surprises Act Enforcement Act; HR 5526 / S 1954, Biosimilar Red Tape Elimination Act; HR 5…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PARKINSON'S FOUNDATION · lobbying firm or registrant: PARKINSON'S FOUNDATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$240,000
Spent on own lobbying
…ssistance, the Office of Management and Budget's rule that revises guidance for federal funding, grants, cooperative agreements, and other forms of assistance. H.R. 3521 | S. 4440, Clinical Trial Modernization Act.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PARKINSON'S FOUNDATION · lobbying firm or registrant: PARKINSON'S FOUNDATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$240,000
Spent on own lobbying
Clinical trials, medication affordability, and medication access for people with Parkinson's. H.R. 3521 | S. 4440, Clinical Trial Modernization Act.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
USAGAINSTALZHEIMERS ACTION · lobbying firm or registrant: USAGAINSTALZHEIMERS ACTION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
$150,000
Spent on own lobbying
…and Related Agencies Appropriations Act, 2027; S. 4632 - Lankford-Hassan Prevent Government Shutdowns Act of 2026; S. 4440 - Clinical Trial Modernization Act; H.R. 3521 - Clinical Trial Modernization Act; S. 4494 - America Cures Act; Issues related to funding for NIH; Issues related to funding for CDC; Issues related to fundin…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER · lobbying firm or registrant: NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
H.R. 3521, Clinical Trial Modernization Act; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy prot…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Taxation/Internal Revenue Code
$1,790,000
Spent on own lobbying
…relief for nonprofit organizations. Issues related to stimulus for nonprofit organizations and increasing charitable giving. Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for ancillary (non…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medical/Disease Research/Clinical Labs
$1,790,000
Spent on own lobbying
Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment, including support for ancillary (no…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL HEALTH COUNCIL · lobbying firm or registrant: NATIONAL HEALTH COUNCIL
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$21,227
Spent on own lobbying
…cess issues. S. 1816/H.R. 3514, Improving Seniors' Timely Access to Care Act. S. 1717/H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act. H.R. 3521/S. 4440, Clinical Trial Modernization Act. S. 2903/H.R. 5509, Safe Step Act. FY 2027 Labor, HHS, Education appropriations for programs affecting people with ch…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTRAZENECA PHARMACEUTICALS LP · lobbying firm or registrant: TODD STRATEGY GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Pharmacy
$80,000
Paid to lobbying firm
…drugs. Policies related to international reference pricing for pharmaceuticals. Pharmaceutical supply chain manufacturing. Pharmaceutical pricing negotiations. H.R.3521/S.4440: Clinical Trials Modernization Act. H.R.5509/S.2903: Safe Step Act. H.R.946/S.1862: Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…ng Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTCT · lobbying firm or registrant: SMITHBUCKLIN CORPORATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Medical/Disease Research/Clinical Labs
$70,000
Paid to lobbying firm
- Labor-HHS Appropriations - CAR-T Therapy clarification - S. 4440/H.R. 3521, the Clinical Trial Modernization Act - OMB Uniform Guidance Oversight
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HEALTHCARE LEADERSHIP COUNCIL · lobbying firm or registrant: HEALTHCARE LEADERSHIP COUNCIL
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$150,000
Spent on own lobbying
H.R. 2213/S. 988, Medical Supply Chain Resilience Act H.R. 2332/S. 1101, States Handling Access to Reciprocity for Employment Act H.R. 3521/S. 4440, Clinical Trial Modernization Act H.R. 4464/S. 3204, Preventive Health Savings Act S. 2120, Older Americans Act Reauthorization Act Regulatory Advocacy…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing